FDA guidance offers clarity on wellness products

The FDA has released a draft guidance offering some clarity on how it defines a low-risk product: A general wellness product becomes a medical device when it refers to its use for a specific disease or condition, according to Medcity News

The draft guidance takes a pragmatic approach, but several wearables companies are working with medical research centers to assess their technology for specific conditions--complicating the picture. FDA is seeking feedback on the guidance for the next 90 days, according to the story.

Read more below:

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”